Famar

Name

Famar

Legal name

FAMAR Health Care Services

Website

https://famar-group.com

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

Keywords

• Pharmaceutical contract manufacturing
• Drug development services
• Sterile injectable manufacturing
• Pharmaceutical distribution services
• Regulatory affairs consulting

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Contract Development Services: R&D and development services for pharmaceutical products including formulation development, analytical services, regulatory support, and tech transfer
2. Contract Manufacturing Services: Commercial manufacturing of pharmaceutical products across various dosage forms for global pharmaceutical companies
3. Product Dossier Sales: Sale of proprietary pharmaceutical dossiers (e.g., BIMATOPROST) with long-term manufacturing agreements
4. Distribution and Logistics Services: Pharmaceutical distribution services in Greece including warehousing, labeling, order fulfillment, and transportation

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

FAMAR is a European pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers development, manufacturing, quality, regulatory and distribution services across a network of 7 production sites, 2 R&D centers and 1 distribution center. The company manufactures more than 1,800 products in 80 international markets, covering solid dose forms, liquids and semi-solids, sterile injectables, lyophilized products, HPAPIs, and consumer care/cosmetics for pharmaceutical companies and biotechs.

Product overview

FAMAR is a leading European pharmaceutical contract development and manufacturing organization (CDMO) providing end-to-end services from development through production to distribution. The company operates as a single integrated platform organized around six core service areas: Pharmaceutical and Consumer Care Development Services, Manufacturing (covering solid dose, liquid/semi-solid, sterile, and consumer care/cosmetic products across seven production sites), Quality Services, Regulatory Affairs, and Logistics/Distribution. The portfolio includes specialized offerings such as HPAPI Products Manufacturing and COMPASS by FAMAR (ready-to-use solutions). The company supplies more than 1,800 products across 80 international markets through its network of 7 production sites, 2 R&D centers, and 1 distribution center.

Differentiator

Problem solved

Functional benefit

Brands

• COMPASS by FAMAR: A business segment providing agile and ready-to-use solutions and services as a leading CDMO

Products and services

• Pharmaceutical Development Services Comprehensive pharmaceutical development including pre-formulation, formulation, investigational medicinal products (IMP), industrialization, and analytical development for sterile liquids, solids and semi-solids. Targeted at pharmaceutical companies requiring R&D and tech transfer support.
• Consumer Care Development Development services for cosmetics, medical devices and biocides including formulation, regulatory compliance, safety assessment, stability studies and technical file preparation. Targeted at consumer care and personal care companies.
• Manufacturing Services Contract manufacturing across solid dose forms (tablets, capsules, effervescent), liquids and semi-solids (syrups, creams, gels), sterile dosage forms (injectables, ampoules, vials, lyophilized), and consumer care/cosmetic products across seven European production sites.
• Quality Services Comprehensive quality services including regulatory intelligence, supplier compliance auditing, analytical method transfer, stability studies, product quality risk management, process validation and annual product quality reviews for pharmaceutical clients.
• Regulatory Affairs Services Scientific and technical regulatory affairs including CTD module preparation, regulatory gap analysis, compliance assessments, regulatory submission strategy and health authority communication support for pharma clients.
• Logistics and Distribution Services End-to-end pharmaceutical distribution including receiving, storage, labeling, repackaging, order processing, transportation (ambient and cold-chain), returns/recalls and inventory control. Processes approximately 735,000 orders and 210 million packs annually across Greece.
• HPAPI Products Manufacturing High Potency Active Pharmaceutical Ingredient handling with dedicated non-GMP areas for toxicological studies and GMP conditions for Safebridge 3A HPAPIs including investigational medicinal products Phase I/II manufacturing.
• COMPASS by FAMAR Agile and ready-to-use CDMO solutions and services segment launched in October 2023, providing faster engagement options for pharmaceutical customers via a dedicated website at compassbyfamar.com.

Quantifiable outcome

• Top 5% of companies assessed by EcoVadis worldwide - Gold medal
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• GE HealthCareflagshipStrategic or Co-development Partner · 19 May 2026Contract manufacturing agreement for iodine-based contrast media production at Homburg site in Germany. Commercial supply expected to start in 2028 with capacity target of 25 million patient doses annually by 2031, expanding GE HealthCare's manufacturing capacity in Europe.
• D-SightcoreStrategic or Co-development Partner · 13 May 2024Strategic partnership for CMC development and clinical batch manufacturing of eye drops solution for diabetic retinopathy treatment. FAMAR provides state-of-the-art GMP manufacturing facilities and CMC expertise while D-Sight contributes innovative therapeutic approach.
• LavipharmcoreStrategic or Co-development Partner · 23 January 2024Collaboration where FAMAR serves as contract manufacturer for Lavipharm's analgesic products Lonarid N and Lonalgal. Partnership enhances domestic Greek pharmaceutical market competitiveness and ensures consistent efficient production.
• Medicom HealthcarecoreStrategic or Co-development Partner · 9 February 2021Asset Purchase Agreement for BIMATOPROST dossier sale with 5-year minimum Manufacturing and Supply Agreement. FAMAR develops and manufactures preservative-free eye drop solution for global commercialization by Medicom.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hovione: European CDMO with particular strength in HPAPI handling, particle engineering, and integrated API-to-drug-product services. Highly comparable to FAMAR's HPAPI and lyophilization capabilities, and competes in the same integrated CDMO segment targeting complex small molecules and potent compounds.
• Recipharm: European-headquartered CDMO offering similar contract development and manufacturing services across solid dose, sterile, and semi-solid dosage forms. Highly comparable in scale, customer base, and service portfolio, and one of the most direct competitive comparables for FAMAR's mid-tier European CDMO positioning.
• Corden Pharma: European CDMO platform offering contract development and manufacturing across APIs, drug products, and packaging for small molecules and biologics. Comparable integrated service model with similar customer base among global pharmaceutical companies seeking mid-tier European supply.
• Aenova: European pharmaceutical CDMO with broad service portfolio covering solid, semi-solid, liquid, and sterile dosage forms across multiple manufacturing sites in Europe. Directly comparable in scale, customer profile (global pharma), and integrated development-to-commercial manufacturing model.
• Fareva: Privately held European CDMO with manufacturing sites across Europe and globally, providing contract manufacturing and packaging for pharmaceuticals, cosmetics, and consumer care. Closely comparable to FAMAR's mix of pharma and consumer care manufacturing across multiple dosage forms and dosage-format specialization.
• Sterling Pharma Solutions: European CDMO focused on API development and manufacturing with growing drug product capabilities. Comparable as a mid-tier European CDMO serving global pharma customers, with overlap in HPAPI handling and small-molecule contract manufacturing.
• Delpharm: European CDMO specializing in sterile and non-sterile pharmaceutical contract manufacturing with multi-site operations across France, Europe, and Canada. Particularly comparable given that Delpharm acquired 5 of FAMAR's former sites (€250M turnover, 1,300 employees) from prior ownership in 2019, directly illustrating service and capability overlap.

Emerging players

• Eurofins CDMO: European CDMO services business spun out of Eurofins, offering contract development and manufacturing for small molecules and biologics. Comparable as a growing European CDMO competing for mid-sized pharma programs, though smaller and more focused than FAMAR's broader dosage form portfolio.

Broad incumbents

• Catalent: One of the largest global CDMOs with extensive capabilities across oral, sterile, and biologic dosage forms including softgel, biologics, and cell/gene therapy. Operates as a broader incumbent than FAMAR in terms of scale, technology breadth, and geographic footprint, but competes for the same pharma outsourcing budgets.
• Piramal Pharma Solutions: Global CDMO with strong HPAPI and sterile injectable capabilities across North America, Europe, and Asia. Overlaps with FAMAR in HPAPI handling, sterile fill-finish, and contract development services, but operates at meaningfully larger scale and global geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

• YouTubeyoutube.com/channel/UCuWvUpOXF35hX2TrJebAWZQ
• LinkedInlinkedin.com/company/famar

Compliance22 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Famar